Stake Sale Speculation At Two PE-Controlled Firms In India: Will Valuations Fly?

Listen to this article

Two top-50 Indian firms are speculated to be on the block with valuations expected to be richer than past multiples paid by buyers. A small, less known life sciences solutions provider is also keen to rope in a CDMO partner. Scrip speaks to a cross-section of experts on the action in deal street.

Deal Action In Store In India • Source: Shutterstock

Election action may be winding down in India, at least for now, but keep an eye on deal street, with at least two domestic firms that feature in the top 50 speculated to be on the block and a small life sciences solutions provider apparently open to a buyout. That’s in addition to on-and-off stake sale rumours pertaining to Cipla Limited.(Also see "'Future Fit' Cipla: Play In Oligonucleotides, Obesity Amid Promoter Stake Action" - Scrip, 17 May, 2024.)

Sale mandates are currently believed to be running for the two private equity (PE)-controlled firms, JB Chemicals & Pharmaceuticals...

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

Jan 23 2026

• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

Dec 09 2025

• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Nov 19 2025

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Nov 12 2025

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Jun 18 2026

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.